-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Sutro Biopharma, Raises Price Target to $57

Benzinga·11/13/2026 15:54:14
Listen to the news
Barclays analyst Lukas Shumway maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $56 to $57.